Proteomics International aims to launch the novel test in Australia through its OxiDx subsidiary inmid 2025, and then expand into the USA via the Company's new US Reference Laboratory [ASX: 28February]
Commercial by mid way through the year.
Timeline for the other 3 have also been stated.
I'm personally not expecting much in revenue until the US market is hit for D, but Endo, released this next quarter will be the game changer.
Let's check in again in 12 months time in terms of significant revenue.
With 41% of shares held by the top 20 and 13% with management, this won't creep up when milestones are hit. IMO the risk now is being left behind if/when institutions want to take a decent stake.
Milesy
Proteomics International aims to launch the novel test in...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $64.65M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 40.0¢ | 38.0¢ | $98.01K | 252.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9722 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 44999 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |